CDISC SEND Updates Nonclinical Drug Developers Need to Know
In this blog, Peggy Zorn explores updates to the Standard for Exchange of Nonclinical Data…
CertaraApril 6, 2026
Virtual Control Groups, Actually: What SEND Makes Possible (and What It Doesn’t)
Learn how SEND enables virtual control groups using historical toxicology data, including key applications, challenges,…
CertaraMarch 4, 2026
Seeing is Understanding: Best Practices for Visualizing Nonclinical Study Data
SEND data visualization: best practices for visualizing nonclinical study data to reveal trends, spot outliers,…
CertaraFebruary 2, 2026
SEND V4.0 – What to Expect and When to Expect It
April 24, 2025 As the Standard for Exchange of Nonclinical Data (SEND) continues to evolve…
CertaraApril 24, 2025
Visualizing SEND Data: Why and How
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 Senior Director, Product Management Peggy is the Customer Success lead for SEND Explorer. She…
CertaraApril 21, 2025
Best Practices for Visualization of Nonclinical Study Data in SEND Format (and Beyond)
Thank you for registering for our webinar, Best Practices for Visualization of Nonclinical Study Data…
CertaraApril 15, 2025
Gain Nonclinical Drug Safety Insights with Real-Time Data Analysis
February 24, 2025 Efficient drug development relies on informed decision-making. For toxicologists, having timely access…
CertaraFebruary 24, 2025
The Benefits of Real-Time Nonclinical Safety Data Analysis
Learn how SEND Explorer software helps nonclinical drug developers streamline performing real-time toxicology assessments of…
CertaraJanuary 27, 2025
Transforming Non-clinical Drug Development with SEND Explorer
Since 1999, Genmab has been developing therapeutic antibodies and antibody-drug conjugates (ADCs) for treating cancer.…
CertaraJuly 8, 2024
